Erlotinib for elderly patients with non‑small‑cell lung cancer: Subset analysis from a population‑based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group

  • Authors:
    • Koichi Kurishima
    • Hiroaki Satoh
    • Takayuki Kaburagi
    • Yoshihiro Nishimura
    • Yoko Shinohara
    • Masaharu Inagaki
    • Takeo Endo
    • Takefumi Saito
    • Kenji Hayashihara
    • Nobuyuki Hizawa
    • Hiroyuki Nakamura
    • Takeshi Nawa
    • Katsunori Kagohashi
    • Koji Kishi
    • Hiroichi Ishikawa
    • Hideo Ichimura
    • Toshio Hashimoto
    • Yukio Sato
    • Mitsuaki Sakai
    • Koichi Kamiyama
    • Takeshi Matsumura
    • Koji Unoura
    • Toshihiko Fukuoka
    • Keiko Uchiumi
    • Akihiro Nomura
    • Kinya Furukawa
  • View Affiliations

  • Published online on: July 23, 2013     https://doi.org/10.3892/mco.2013.154
  • Pages: 828-832
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The incidence and mortality of lung cancer have increased worldwide over the last decades, with an observed increased incidence particularly among elderly populations. It has not yet been determined whether erlotinib therapy exhibits the same efficacy and safety in elderly and younger patients with non‑small‑cell lung cancer (NSCLC). The aim of this retrospective subgroup analysis of data from a population‑based observational study was to assess the efficacy and safety of erlotinib in an elderly (≥75 years, n=74) and a younger group of patients (<75 years, n=233) who received treatment for NSCLC. The time to treatment failure was similar in the elderly [median, 62 days; 95% confidence interval (95% CI): 44‑80 days] compared with the younger group (median, 46 days; 95% CI: 35‑53 days) (P=0.2475). The overall survival did not differ between the elderly and younger groups (median, 170 days; 95% CI: 142‑239 days vs. median, 146 days; 95% CI: 114‑185 days, respectively) (P=0.7642). The adverse events did not differ in incidence between the groups and were manageable, regardless of age. Among the NSCLC patients receiving erlotinib treatment, the outcomes of the elderly (≥75 years) and younger (<75 years) groups of patients were similar in our population‑based observational study.
View Figures
View References

Related Articles

Journal Cover

September 2013
Volume 1 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kurishima, K., Satoh, H., Kaburagi, T., Nishimura, Y., Shinohara, Y., Inagaki, M. ... Furukawa, K. (2013). Erlotinib for elderly patients with non‑small‑cell lung cancer: Subset analysis from a population‑based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group. Molecular and Clinical Oncology, 1, 828-832. https://doi.org/10.3892/mco.2013.154
MLA
Kurishima, K., Satoh, H., Kaburagi, T., Nishimura, Y., Shinohara, Y., Inagaki, M., Endo, T., Saito, T., Hayashihara, K., Hizawa, N., Nakamura, H., Nawa, T., Kagohashi, K., Kishi, K., Ishikawa, H., Ichimura, H., Hashimoto, T., Sato, Y., Sakai, M., Kamiyama, K., Matsumura, T., Unoura, K., Fukuoka, T., Uchiumi, K., Nomura, A., Furukawa, K."Erlotinib for elderly patients with non‑small‑cell lung cancer: Subset analysis from a population‑based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group". Molecular and Clinical Oncology 1.5 (2013): 828-832.
Chicago
Kurishima, K., Satoh, H., Kaburagi, T., Nishimura, Y., Shinohara, Y., Inagaki, M., Endo, T., Saito, T., Hayashihara, K., Hizawa, N., Nakamura, H., Nawa, T., Kagohashi, K., Kishi, K., Ishikawa, H., Ichimura, H., Hashimoto, T., Sato, Y., Sakai, M., Kamiyama, K., Matsumura, T., Unoura, K., Fukuoka, T., Uchiumi, K., Nomura, A., Furukawa, K."Erlotinib for elderly patients with non‑small‑cell lung cancer: Subset analysis from a population‑based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group". Molecular and Clinical Oncology 1, no. 5 (2013): 828-832. https://doi.org/10.3892/mco.2013.154